Disease tracking markers for Alzheimer's disease at the prodromal (MCI) stage. - Wikidata - wikimedia - TriplyDB

Disease tracking markers for Alzheimer's disease at the prodromal (MCI) stage.

Disease tracking markers for Alzheimer's disease at the prodromal (MCI) stage.

http://www.wikidata.org/entity/Q34039972

about

Mesenchymal stem cells-based therapy as a potential treatment in neurodegenerative disorders: is the escape from senescence an answer?Eye movement analysis and cognitive processing: detecting indicators of conversion to Alzheimer's disease A review of β-amyloid neuroimaging in Alzheimer's disease.Genome-wide significant risk factors for Alzheimer's disease: role in progression to dementia due to Alzheimer's disease among subjects with mild cognitive impairment Theta and Alpha Alterations in Amnestic Mild Cognitive Impairment in Semantic Go/NoGo Tasks.Reliability of EEG Interactions Differs between Measures and Is Specific for Neurological Diseases.CSF and Brain Indices of Insulin Resistance, Oxidative Stress and Neuro-Inflammation in Early versus Late Alzheimer's Disease Smoking and increased Alzheimer's disease risk: a review of potential mechanisms A systematic review of the evidence that brain structure is related to muscle structure and their relationship to brain and muscle function in humans over the lifecourse.Cost-effectiveness of magnetic resonance imaging with a new contrast agent for the early diagnosis of Alzheimer's disease.Attitudes of the German general population toward early diagnosis of dementia--results of a representative telephone survey.Predicting AD conversion: comparison between prodromal AD guidelines and computer assisted PredictAD tool Apolipoprotein E, gender, and Alzheimer's disease: an overlooked, but potent and promising interaction Emerging biomarkers in cognition.Protection against Brain Atrophy by Anti-dementia Medication in Mild Cognitive Impairment and Alzheimer's Disease: Meta-Analysis of Longitudinal Randomized Placebo-Controlled Trials The Road Ahead to Cure Alzheimer's Disease: Development of Biological Markers and Neuroimaging Methods for Prevention Trials Across all Stages and Target Populations White matter integrity in highly traumatized adults with and without post-traumatic stress disorder.Neurogranin and YKL-40: independent markers of synaptic degeneration and neuroinflammation in Alzheimer's disease.Altered Cortical Synaptic Plasticity in Response to 5-Hz Repetitive Transcranial Magnetic Stimulation as a New Electrophysiological Finding in Amnestic Mild Cognitive Impairment Converting to Alzheimer's Disease: Results from a 4-year Prospective Co Role of the Transforming-Growth-Factor-β1 Gene in Late-Onset Alzheimer's Disease: Implications for the Treatment Neuroimaging referral for dementia diagnosis: The specialist's perspective in Ireland.Longitudinal cerebrospinal fluid biomarker measurements in preclinical sporadic Alzheimer's disease: A prospective 9-year study A semi-mechanism approach based on MRI and proteomics for prediction of conversion from mild cognitive impairment to Alzheimer's disease Imaging the Alzheimer brain.Free and cued recall memory in Parkinson's disease associated with amnestic mild cognitive impairment FKBP5 genotype and structural integrity of the posterior cingulum Subcortical Shape Changes, Hippocampal Atrophy and Cortical Thinning in Future Alzheimer's Disease Patients.Interaction of Cigarette Smoking History With APOE Genotype and Age on Amyloid Level, Glucose Metabolism, and Neurocognition in Cognitively Normal Elders.Tau pathology and parietal white matter lesions have independent but synergistic effects on early development of Alzheimer's disease Revolution of Alzheimer Precision Neurology Passageway of Systems Biology and Neurophysiology.Brain Monitoring Devices in Neuroscience Clinical Research: The Potential of Remote Monitoring Using Sensors, Wearables, and Mobile Devices.Sleep Disorders Associated With Alzheimer's Disease: A Perspective.Systematic Review on Resting-State EEG for Alzheimer's Disease Diagnosis and Progression Assessment

P2860

Q26801122-409D04B7-3DA1-4B3B-BA8D-A67B450BDF84 Q27009241-C43BD2C4-AF52-4C89-9605-FA40D7BCC7AD Q30870063-D390C28A-505C-4706-895A-B94EB5E3007B Q33629452-EA06A463-4FFD-4242-B402-9154442995C1 Q33716680-AC7E850C-015D-4BFA-9285-78B49EFFA022 Q33870959-EC93CA70-C937-47E0-A9F5-0C52A01A26DD Q33896118-4793E778-706F-4253-A881-8C574CCAB985 Q33902721-569ECF3B-96A9-4D9E-8218-03B419C69C31 Q33929253-AB94D8E0-7194-4F58-B6F2-625239693AA6 Q34245127-DEF6A86B-9145-461B-885D-E622A0B682E5 Q34500715-4F98DDF5-E1E8-4AFC-AF96-F279853A5D60 Q34592576-AA341755-0DB1-45A5-9713-A913750B9BE0 Q34808510-2B6314CA-12BD-44AC-B8FF-DA52657670FF Q35008258-5E8E0EAC-3CF0-408B-B7CE-561BF033D3E7 Q35669030-8FFB5AED-A647-4727-A2FC-11E35F6D0A88 Q36165011-1E3684BA-00CA-49D6-8EDF-E3501FE044B8 Q36323582-F91752E2-B5F3-407B-818D-4B67412D577F Q36402008-587E7813-7653-44BF-A3C5-F737CA5019B0 Q36452915-5562D0E7-000D-4A73-BA9F-C3AE3450FB15 Q36798886-716E8600-8427-4897-A0C1-7E5985737ADD Q36926723-0FAEB918-0BD1-4312-BB24-5F8F92FE011C Q36933698-7098B7AA-84C2-47DC-9B8A-923BA1E7311B Q36976353-293E1E10-332F-4533-9223-0AC68D3C1360 Q37141502-B98DC811-40FD-47A7-8817-5BD8E181DEE4 Q37510003-F436F721-55D8-4C3F-9D11-4535333B11E8 Q37642444-EFB132E8-9AAB-44E7-A195-96D94A17D20E Q37683684-EA619737-4763-418A-958F-162B780FB852 Q38413816-7A234BB3-9CF5-487F-BA6B-E1408F62A358 Q40787474-B5A9546F-6172-4DA7-B295-11238B767D4E Q51760905-571B1B49-3D86-4B0E-8A73-A523B398A8EC Q52343127-0ABF294A-EC05-41D8-BE95-D0F5D1925F6C Q55093548-358051E0-7589-47B4-8DA2-6FD34C795F85 Q58583583-23A3BCB5-D150-4CDC-B1F3-714A1E61FF09

P2860

Disease tracking markers for Alzheimer's disease at the prodromal (MCI) stage.

http://www.wikidata.org/entity/Q34039972

description

2011 nî lūn-bûn

@nan

2011 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Disease tracking markers for Alzheimer's disease at the prodromal (MCI) stage.

@ast

Disease tracking markers for Alzheimer's disease at the prodromal (MCI) stage.

@en

Disease tracking markers for Alzheimer's disease at the prodromal

@nl

type

label

Disease tracking markers for Alzheimer's disease at the prodromal (MCI) stage.

@ast

Disease tracking markers for Alzheimer's disease at the prodromal (MCI) stage.

@en

Disease tracking markers for Alzheimer's disease at the prodromal

@nl

prefLabel

Disease tracking markers for Alzheimer's disease at the prodromal (MCI) stage.

@ast

Disease tracking markers for Alzheimer's disease at the prodromal (MCI) stage.

@en

Disease tracking markers for Alzheimer's disease at the prodromal

@nl

P1433

Q34039972-81878D06-0408-4230-8B7F-E6A76831681C

P1476

Q34039972-2410D145-2CB2-493B-8DAA-FBC3F6651473

P2093

Q34039972-11AB01A4-A4E0-4104-BB83-A427B9DD7C22

Q34039972-22921BA2-C917-4B51-8270-709E2FF04539

Q34039972-2C9FACD1-77EC-4B8B-B18F-B42CFA583338

Q34039972-477993A4-71E9-4B73-B715-62B367AC6C0A

Q34039972-54714222-F18D-46B7-831A-96C73CF7BC16

Q34039972-63306C93-6945-474B-AC7D-5FDE6EB8DDF0

Q34039972-6333CBDC-2530-471B-8842-127FB891F0A4

Q34039972-82182173-B2E5-40D6-B959-5EB47F83CBD7

Q34039972-A25454AC-8622-4354-9ECE-F691D0B11B83

Q34039972-BD0B8E20-F935-4662-8EC5-2FDD6A28585A

P304

Q34039972-44D82B5E-0EE7-4F93-9582-CF5E787F91BE

P31

Q34039972-8FF0FA27-CB1F-447A-9314-5F16CD3B68D2

P356

Q34039972-01927D47-1F10-48E7-9B5F-50EB1F7358CB

P478

Q34039972-867D9468-D515-46CD-A9EA-430494C99FE1

P50

Q34039972-0F62EBB4-1F4D-4A65-9D89-A0B7A4353D5C

Q34039972-1ED0751E-7826-4EA1-B174-993EFCEBC18F

Q34039972-569A9D88-7223-4183-B91F-AF2DCBC91936

Q34039972-6B09AF11-A70D-4DA4-8F6E-91376D9E88EA

Q34039972-96415C6D-BFD0-4794-80E6-74CE5D9CE81C

Q34039972-987F7E91-A4E1-4CC1-9B23-FBF5F559E146

Q34039972-9B624B73-C5E2-482F-951C-7E247E68622A

Q34039972-C7D457E9-2F85-4417-AAFD-01352A77030C

Q34039972-FBFF640D-21B6-4D29-9C40-1A502B04C6DB

P577

Q34039972-EE8C42FA-54D9-4CFE-AFEA-F0DEE0188FE3

P5875

Q34039972-FD5544E6-D645-4DF7-89D3-A6552960550B

P698

Q34039972-EE7CBA85-5BC5-41BA-883A-DB5B7F7EB8A1

P921

Q34039972-B023D64C-19D4-4D4B-A8A2-34DC0BC6AA4D

P356

P1433

Journal of Alzheimer's Disease

P1476

Disease tracking markers for Alzheimer's disease at the prodromal (MCI) stage

@en

P2093

Anna Caroli

http://www.w3.org/2001/XMLSchema#string

Ceri Davis

http://www.w3.org/2001/XMLSchema#string

Elaine Irving

http://www.w3.org/2001/XMLSchema#string

Fabrizio Vecchio

http://www.w3.org/2001/XMLSchema#string

Hans-Wolfgang Klafki

http://www.w3.org/2001/XMLSchema#string

Hans-goran Hårdemark

http://www.w3.org/2001/XMLSchema#string

Jans Wiltfang

http://www.w3.org/2001/XMLSchema#string

Luca Venturi

http://www.w3.org/2001/XMLSchema#string

Mira Didic

http://www.w3.org/2001/XMLSchema#string

Olivier Blin

http://www.w3.org/2001/XMLSchema#string

P304

159-199

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3233/JAD-2011-0043

http://www.w3.org/2001/XMLSchema#string

P478

26 Suppl 3

http://www.w3.org/2001/XMLSchema#string

P50

Giovanni B. Frisoni

Michela Pievani

Claudio Babiloni

David Bartrés-Faz

Alberto Redolfi

P577

2011-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51693674

http://www.w3.org/2001/XMLSchema#string

P698

21971460

http://www.w3.org/2001/XMLSchema#string

P921

Alzheimer's disease